Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:PACB) with a Sector Outperform and lowers the price target from $8 to $7.
Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $7
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.